A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Part of paid clinical trials in Scottsdale, Arizona.
- Sponsor
- Novartis Pharmaceuticals
- Study ID
- NCT06649110
- Phase
- PHASE1/PHASE2
- Status
- Recruiting
Conditions
- Healthy Volunteers, Pulmonary Arterial Hypertension
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 100 Years
- Healthy Volunteers
- Accepted
Interventions
- LTP — DRUGLTP001
- Placebo — DRUGPlacebo
Study Details
A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)
Key Dates
- Start date
- Oct 24, 2024
- Status verified
- Apr 2026
- Primary completion
- Nov 29, 2028
- Completion
- Dec 31, 2028
Study Design
- Enrollment
- 232 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: LTP001 Dose 1
- Experimental: LTP001 Dose 2
- Experimental: LTP001 Dose 3
- Placebo Comparator: Placebomatching placebo
Primary Outcome Measure
Part A- Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs) [ Time Frame: Baseline to Day 35 ]
Central Contacts
- Novartis Pharmaceuticals1-888-669-6682
- Novartis Pharmaceuticals+41613241111
Locations (19)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Arizona Pulmonary Specialists Ltd | Scottsdale | Arizona | 85258 | +1 602 271 0832 Akshay Muralidhar (PRINCIPAL_INVESTIGATOR) |
| UC Irvine Medical Center | Orange | California | 92868-3298 | +1 714 456 6037 Bassam Yaghmour (PRINCIPAL_INVESTIGATOR) |
| Stanford Medical Center | Stanford | California | 94305 | +1 650 725 5495 Roham Zamanian (PRINCIPAL_INVESTIGATOR) |
| Univ Colorado Hospital | Aurora | Colorado | 80045 | +1 720 848 6567 David B Badesch (PRINCIPAL_INVESTIGATOR) |
| Central Florida Pulmonary Group | Orlando | Florida | 32803-5734 | +1 407 841 1100 Syed Mobin (PRINCIPAL_INVESTIGATOR) |
| University of South Florida | Tampa | Florida | 33606-3475 | +1 813 844 7137 Ricardo Restrepo-Jaramillo (PRINCIPAL_INVESTIGATOR) |
| Emory University School of Medicine | Atlanta | Georgia | 30322 | +1 404 778 3261 Micah Fisher (PRINCIPAL_INVESTIGATOR) |
| U of Kansas Medical Center | Kansas City | Kansas | 66160 | +1 913 588 9722 Leslie Spikes (PRINCIPAL_INVESTIGATOR) |
| Norton Infectious Diseases Specialists | Louisville | Kentucky | 40202 | +1 502 587 8000 John Wesley McConnell (PRINCIPAL_INVESTIGATOR) |
| Tufts Medical Center | Boston | Massachusetts | 02111 | +1 617 636 4288 Nicholas Hill (PRINCIPAL_INVESTIGATOR) |
| Lahey Hospital and Medical Center | Burlington | Massachusetts | 01805 | +1 781 744 3874 Ioana Preston (PRINCIPAL_INVESTIGATOR) |
| Sky Integrative Medical Center SKYCRNG PPDS | Ridgeland | Mississippi | 39157-5179 | Bob Hutchins (PRINCIPAL_INVESTIGATOR) |
| Summit Health Eastside Clinic | Bend | Oregon | 97701 | Jeremy Feldman (PRINCIPAL_INVESTIGATOR) |
| Allegheny General Hospital | Pittsburgh | Pennsylvania | 15212-4756 | Hayah Kassis-George (PRINCIPAL_INVESTIGATOR) |
| Statcare Pulmonary Consultants | Knoxville | Tennessee | 37919 | John Swisher (PRINCIPAL_INVESTIGATOR) |
| PPD Development LP | Austin | Texas | 78744 | +1 512 447 2985 Jia Chang (PRINCIPAL_INVESTIGATOR) |
| UT Southwestern Medical Center | Dallas | Texas | 75390 | +1 214 645 6488 Kelly Chin (PRINCIPAL_INVESTIGATOR) |
| The University of Utah | Salt Lake City | Utah | 84132-0001 | +1 801 213 4086 Katharine Clapham (PRINCIPAL_INVESTIGATOR) |
| Pul Ass Richmond Inc P A R | Richmond | Virginia | 23230-1709 | Shilpa Johri (PRINCIPAL_INVESTIGATOR) |